

Het effect van sessiefrekwентie op de behandeling van PTSS t.g.v. trauma's uit de kindertijd.

Gepubliceerd: 25-04-2018 Laatst bijgewerkt: 18-08-2022

1. A frequency of two sessions per week is more effective than a frequency of one session per week. 2. Treatment type (EMDR vs.) ImRs moderates the frequency effect. 3. The frequency effect is mediated by memory, relationships and motivational...

Ethische beoordeling	Niet van toepassing
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON25041

Bron

NTR

Verkorte titel

IREM-Freq

Aandoening

PTSD due to trauma(s) that took place before the age of 16.

PTSS t.g.v. van trauma's die plaatsvonden in de kindertijd, voor de leeftijd van 16 jaar.

Ondersteuning

Primaire sponsor: University of Amsterdam, Netherlands;University of Western Australia, Australia;University of Munich, Germany;University of Münster, Germany;University of Lübeck, Germany;Hunter New England Mental Health Service, Newcastle, Australia;Sexual Assault Resource Centre, Perth, Australia; PsyQ Amsterdam, Beverwijk, the Netherlands;GGZ Oost-Brabant, Helmond, the Netherlands;GGZ Noord-Holland Noord, Heerhugowaard, the Netherlands;Sinai Center, Amstelveen, the Netherlands; ABATE, Enkhuizen, the Netherlands

Overige ondersteuning: Initiators

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

CAPS-5 total severity score, assessed at 24 weeks after start of treatment

Toelichting onderzoek

Achtergrond van het onderzoek

This international randomized clinical trial (RCT) investigates the effects of frequency of treatment sessions of Imagery Rescripting (ImRs) and EMDR as treatments of PTSD due to childhood trauma. Participants are randomized to ImRs or EMDR (both 12 sessions), either twice a week, or once a week a session (2x2 design). The primary outcome is change in PTSD severity as assessed with the CAPS-5. Various secondary measures are assessed, including guilt, shame, and anger. Factors that might explain an effect of session frequency are investigated both among patients and therapists. We will also develop an index that predicts which patient is better off with what treatment, frequency, or treatment-frequency combination (personalized medicine). There are 11 participating sites, 2 Australian, 3 German, and 6 Dutch sites (2 of the academic network PsyQ-UvA; 1 of GGZ Oost-Brabant; 1 of GGZ-NHN; 1 of Sinaï Centrum; 1 of ABATE). Total minimum N = 220, possibly N=280.

Senior researchers:

Arnoud Arntz (UvA); Thomas Ehring (LMU, München); Eva Fassbinder (UKSH, Lübeck); Chris Lee (UWA, Perth); Nexh Morina (WWU, Münster)

Note that ethical approval has been obtained from the ethical committee of the University of Amsterdam for the Dutch sites. German and Australian sites are in the process of obtaining ethical approval from local ethical committees.

Doel van het onderzoek

1. A frequency of two sessions per week is more effective than a frequency of one session per week.
2. Treatment type (EMDR vs.) ImRs moderates the frequency effect.

3. The frequency effect is mediated by memory, relationships and motivational factors in both patient and therapist.

Onderzoeksopzet

baseline

6-8 weeks (i.e., post resp. halfway treatment for high resp. low frequency arms)

12-16 weeks (i.e., post treatment for low frequency)

24 weeks

52 weeks

there might be an additional pre-wait assessment if natural waitlist is > 5 weeks at the participating site.

Onderzoeksproduct en/of interventie

EMDR, 12 sessions, delivered once a week

EMDR, 12 sessions, delivered twice a week

ImRs, 12 sessions, delivered once a week

ImRs, 12 sessions, delivered twice a week

Contactpersonen

Publiek

University of Amsterdam

Arnoud Arntz

Amsterdam 1018 AX

The Netherlands

0646705191

Wetenschappelijk

University of Amsterdam

Arnoud Arntz

Amsterdam 1018 AX
The Netherlands
0646705191

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- PTSD as defined by the DSM-5, assessed with the SCID-5-CV or SCID-5-RV and the CAPS.
- PTSD as main complaint
- Duration of PTSD > 3 months.
- Index trauma happened before the age of 16
- patient agrees that index trauma is focus of treatment
- If a recent trauma occurred: recent trauma happened more than 6 months ago
- Age between 18 and 70
- Ability to understand, read, write and speak country's language. In German and Dutch sites the English language is also possible, if the site has research assistants and therapists of both conditions that are sufficiently fluent in English.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Acute PTSD
- DSM-5 substance use disorder, severity level moderate or severe (defined by 4 or more symptoms). (After 6 weeks of abstinence participation is possible).
- Use of benzodiazepine (patients are motivated to stop benzodiazepine use in order to follow treatment protocol) (After 2 weeks of abstinence participation is possible)
- Comorbid psychotic disorder
- DSM-5 Bipolar disorder, type 1 (current or past)

- Acute suicide risk
- IQ < 80
- Serious neurological problems like dementia
- Scheduled to begin another form of PTSD treatment
- PTSD focused therapy within the past 3 months. If patients are in treatment for PTSD, there should be a 3-months treatment free period before they can participate in the study. PTSD-focused treatment includes emotion-regulation treatments for PTSD like STAIR and other PTSD-focused treatments, but not general supportive treatments.
- Patients should not start with any form of psychological treatment or medication during screening or during the study's treatment or waitlist period. Medication should be on a stable level for 3 months, if not stopped. (Non-PTSD focused supportive treatment may be continued during wait and screening, but not during the study treatment and study post-treatment follow-up period (i.e., up to the 24 weeks assessment).
- Not able to plan 12 sessions of 90 minutes within 6 to 8 weeks (time in between the sessions needs to be at least 2 days), or 12 sessions within 12 to 16 weeks (time in between sessions needs to be at least 6 days and on the average a week or longer).

COVID-19 related ad hoc exclusion of participants that could not be seen face-to-face during all their treatment sessions. The research into factors explaining the possible superiority of the twice-a-week treatment require face-to-face treatment because of the pre-session assessment procedures of patients and therapists. The (temporary) closure of mental health institutes in Australia, Germany, and the Netherlands, has lead the study board to take this decision. Moreover, because of excluding these participants, and the slowing down of recruitment during the pandemic, the stop date has been provisionally extended with at least a year.

Because of capacity problems 3 PsyQ sites did not start participation, only the Amsterdam and Beverwijk PsyQ sites participate. To compensate, the ABATE mental health institute joined the study.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd

Blindering:	Enkelblind
Controle:	Geneesmiddel

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-06-2018
Aantal proefpersonen:	220
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nog niet bepaald

Toelichting

requests can be submitted by researchers with an appropriate research question and statistical analysis plan, with guarantees of privacy regulations and not interfering with publication plans of the study board.

Ethische beoordeling

Niet van toepassing	
Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register ID

NTR-new NL6965

NTR-old NTR7153

Ander register Ethics Review Board (FMG-UvA) University of Amsterdam : 2017-CP-8638

Resultaten

Samenvatting resultaten

none.